Stock Evaluator: Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. NBIX

$166.80 -18.70 -10.08%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 4,584,218
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics NBIX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $18,652.0 $251.9 85%
Shares Out (Mil) 103.4 50.8 63%
Institutional Ownership 98.9% 92.0% 83%
Float (Mil) 99.3 40.5 61%
Beta 0.34 0.95 19%
Avg Daily Volume (000s) 1,225 447 74%
Price Change
(52-week)
38.2% 54.2% 75%
Growth NBIX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 22.3% 14.0% 84%
Net Income (5yr) 3.3% (9.8%) 44%
EPS (5yr) 2.3% 16.3% 34
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 43.2% (15.6%) 92%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 15 16 15
Current EPS $1.960 $9.933 $12.660
Month Ago EPS $2.167 $10.184 $12.597
# Rev Up 0 1 1
# Rev Down 1 0 0
Three Months Ago EPS $1.955 $9.942 $13.211
Year/Year Chg 2.6% 112.7% 225.7%
Financials NBIX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3,102 $39 67%
Net Income (TTM) (Mil) $669 ($43) 82%
EPS (TTM) $6.706 ($1.600) 91%
Operating Cash Flow (TTM) (Mil) $864 ($30) 79%
Net Cash Flow (TTM) (Mil) $72 $3 75%
Long-Term Debt (Q1) (Mil) $406 $5 57%
Enterprise Value (Q1) (Mil) $14,456 $182 79%
Valuation NBIX Industry
Median
Percentile
(All Stocks)
P/B 5.48 2.60 80%
P/E 28.5 18.6 66%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 12.4 0.9 95%
Ratios NBIX Industry
Median
Percentile
(All Stocks)
Gross Margin 64.4% 63.8% 76%
Net Margin 21.6% (64.7%) 81%
ROA 15.6% (49.7%) 94%
ROE 22.5% (55.4%) 82%
Liabilities to Assets 30.5% 30.3% 22%
F-Score 7 3 84%

Neurocrine Biosciences, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors